Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epclusa + Ribavirin for HCV Retreatment
NCT02300103Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of velpatasvir in hepatitis C virus infection, sponsored by Gilead Sciences. Started Dec 2014; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02300103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300103.